NORTH CHICAGO, Ill – AbbVie (ABBV) has reached a significant advancement in the development of upadacitinib (RINVOQ), a JAK inhibitor for autoimmune hair loss diseases, [Read More…]
Novo Nordisk’s new studies presented at ESC Congress 2025 highlight semaglutide’s powerful cardiovascular benefits for people with diabetes and obesity, showing substantial reductions in heart attack, stroke, and cardiovascular death risks with Wegovy, Ozempic, and Rybelsus.
AbbVie has finalized its acquisition of Capstan Therapeutics, gaining access to a groundbreaking in vivo tLNP CAR-T cell therapy and proprietary RNA delivery platform for B cell-mediated autoimmune diseases.
Novo Nordisk’s Wegovy has received FDA approval to treat MASH, a serious liver disease linked to obesity and diabetes. This new indication highlights Wegovy’s role in improving liver fibrosis and reversing liver damage alongside lifestyle changes.
Omeros Corporation reported a sharply reduced net loss in Q2 2025, strengthened its balance sheet through debt restructuring and new capital, and advanced its lead drug narsoplimab toward regulatory approvals.
Gilead Sciences reports a successful second quarter for 2025, with total revenue climbing to $7.1 billion, driven by a 7% increase in its HIV franchise sales. Diluted EPS rose to $1.56. Following these strong results, Gilead has raised its full-year 2025 guidance, now expecting product sales between $28.3 billion and $28.7 billion.
The combination of PADCEV and KEYTRUDA has shown a significant improvement in both event-free survival and overall survival for patients with muscle-invasive bladder cancer who are not eligible for cisplatin-based chemotherapy.
The US FDA has granted priority review to GSK’s new drug application for gepotidacin, a potential new oral treatment for uncomplicated urogenital gonorrhea.
Eyestem Research has successfully closed an oversubscribed funding round, securing $10 million to accelerate the development of Eyecyte-RPE™, its investigational cell therapy for dry age-related macular degeneration (dry AMD).
Eli Lilly and Company announced that its investigational oral GLP-1 receptor agonist, orforglipron, delivered an average weight loss of 27.3 lbs in the Phase 3 ATTAIN-1 trial. The once-daily pill demonstrated a safety profile consistent with existing injectable GLP-1 therapies and also showed improvements in cardiovascular risk factors.
